XERIS BIOPHARMA HOLDINGS, INC. Defined Contribution Plan, Employer Discretionary Contribution Amount
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Defined Contribution Plan, Employer Discretionary Contribution Amount of $3.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs
us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for the quarter ending 2022-03-31 was $700.00K, a 16.67% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for the quarter ending 2021-03-31 was $600.00K.
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for fiscal 2025 was $3.20M, a 60.00% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for fiscal 2024 was $2.00M, a 16.67% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for fiscal 2023 was $2.40M, a 41.18% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. defined contribution plan, employer discretionary contribution amount for fiscal 2022 was $1.70M, a 142.86% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Employer Discretionary Contribution Amount 3 month | Defined Contribution Plan, Employer Discretionary Contribution Amount 12 month |
|---|---|---|
| 2025-12-31 | $3.20M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $2.00M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $2.40M 10-K · filed 2026-03-02 | |
| 2022-12-31 | $1.70M 10-K · filed 2025-03-06 | |
| 2022-03-31 | $700.00K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $700.00K 10-K · filed 2024-03-06 | |
| 2021-03-31 | $600.00K 10-Q · filed 2022-05-11 | |
| 2020-12-31 | $600.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |